The Gut-Brain Axis & Inflammatory bowel disease

The gut microbiome plays a fundamental role on the education and function of a healthy immune system. Immunological imbalance is the cause of numerous human disorders including autoimmune diseases and metabolic disorders frequently associated with inflammatory processes. It is possible to explore the novel mechanisms involved in maintaining the immune system homeostasis from a variety of biological and technical perspectives. Various metabolic disorders are associated with changes in inflammatory tone throughout the gastrointestinal wall. However, to date, few mechanisms have been clearly established. The endocannabinoid system and its related bioactive molecules participate in multiple central and peripheral physiological processes that affect metabolic, gastrointestinal and neuroimmune regulatory mechanisms, demonstrating a unique modulatory role and contributing to the maintenance of the organism’s homeostasis through broad technical embodiments identified and developed by Biotica Bio. The intestinal microbiota and the central nervous system are connected through multiple bidirectional pathways involving neural, endocrine and immune signaling that constitute the gut-brain axis. The gut-brain axis modulates the gastrointestinal tract and enteric nervous system via sympathetic and parasympathetic branches of the autonomic nervous system, influencing widespread metabolic, inflammatory, and nervous conditions that affect millions of people.

Inflammatory bowel diseases (IBD), typically classified as either Crohn’s disease (CD) or ulcerative colitis (UC), are chronic, debilitating conditions characterized by relapsing and remitting episodes of gastrointestinal inflammation. As the incidence and prevalence have increased over the past 50 years, so has our understanding of the pathophysiology of this complex, immunologically-mediated disease process. While various environmental risk factors have been identified, an explanation for the increased rate of IBD diagnoses in the United States and abroad remains elusive. IBD affects approximately 2 million Americans, and its peak onset is in persons 15 to 30 years of age. Symptoms range from mild lifestyle inconvenience to debilitating and persistent pain. Crohn's disease generally involves the ileum and colon, but it can affect any region of the intestine, often discontinuously. Ulcerative colitis involves the rectum and may affect part of the colon or the entire colon (pancolitis) in an uninterrupted pattern. In Crohn's disease the inflammation is often present throughout the intestinal tissues, whereas in ulcerative colitis the inflammation is typically confined to the mucosa. In particularly severe cases, Crohn's disease can lead to intestinal granulomas, strictures, and fistulas.

Biological therapeutics currently on the market sacrifice a patient’s fully functional immune system in exchange for limited IBD symptom management. Biotica Bio’s technology and approach avoids this expensive, and potentially devastating, trade off and may provide patients with a much needed therapy that can quickly improve their quality of life.